Wells Fargo & Company MN Lowers Stock Position in Haleon plc (NYSE:HLN)

Wells Fargo & Company MN lowered its holdings in Haleon plc (NYSE:HLN - Free Report) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,256,773 shares of the company's stock after selling 44,794 shares during the quarter. Wells Fargo & Company MN owned 0.07% of Haleon worth $31,070,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Sierra Ocean LLC purchased a new stake in Haleon in the 4th quarter valued at about $26,000. Versant Capital Management Inc raised its stake in shares of Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after acquiring an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Haleon in the 4th quarter worth approximately $35,000. Toronto Dominion Bank boosted its position in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after purchasing an additional 3,470 shares during the period. Finally, Spire Wealth Management purchased a new position in shares of Haleon during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HLN. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. HSBC reaffirmed a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $10.95.

Haleon Stock Up 1.3 %

Shares of NYSE HLN traded up $0.14 during midday trading on Wednesday, hitting $10.26. 5,870,985 shares of the company's stock were exchanged, compared to its average volume of 7,041,082. The firm's fifty day simple moving average is $10.06 and its 200-day simple moving average is $9.81. The company has a market cap of $46.33 billion, a PE ratio of 30.16, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a twelve month low of $8.04 and a twelve month high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Research analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a $0.1166 dividend. This is an increase from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon's payout ratio is presently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.